Research graph
References from Phase I clinical trials in patients≥80. Local targets link to admitted publications; unresolved targets remain external evidence.
Relation between age and clearance rate of nine investigational anticancer drugs from phase I pharmacokinetic data
10.1007/bf00686507 · 1994 · External reference
Barriers to clinical trial participation by older women with breast cancer
10.1200/jco.2003.09.124 · 2003 · External reference
Oncologists' reluctance to accrue patients onto clinical trials: an Illinois Cancer Center study
10.1200/jco.1991.9.11.2067 · 1991 · External reference
Underrepresentation of patients 65years of age or older in cancer-treatment trials
10.1056/nejm199912303412706 · 1999 · External reference
Annual summary of vital statistics:
10.1542/peds.2009-2416 · 2007 · External reference
Phase I trial of fludarabine, bortezomib and rituximab for relapsed and refractory indolent and mantle cell non-Hodgkin lymphoma
10.1111/j.1365-2141.2009.07836.x · 2009 · External reference
Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas
10.1200/jco.2005.16.584 · 2005 · External reference
Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of renal dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group
10.1200/jco.2007.13.3819 · 2008 · External reference
Phase I trial of three-weekly docetaxel, carboplatin and oral lenalidomide (Revlimid) in patients with advanced solid tumors
10.1007/s10637-006-9025-4 · 2007 · External reference
Phase I clinical and pharmacokinetic study of oxaliplatin, irinotecan and capecitabine
10.1007/s00280-008-0754-2 · 2009 · External reference
A phase I study of rebeccamycin analog in combination with oxaliplatin in patients with refractory solid tumors
10.1007/s10637-009-9322-9 · 2011 · External reference
A phase I trial of prolonged oral etoposide and liposomal doxorubicin in ovarian, peritoneal, and tubal carcinoma: a gynecologic oncology group study
10.1006/gyno.2002.6584 · 2002 · External reference
Sequential prolonged oral topotecan and prolonged oral etoposide as second-line therapy in ovarian or peritoneal carcinoma: a phase I Gynecologic Oncology Group study
10.1016/j.ygyno.2005.12.003 · 2006 · External reference
A phase I study of oral topotecan and pegylated liposomal doxorubicin (doxil) in platinum-resistant ovarian and peritoneal cancer
10.1097/coc.0b013e31816a6221 · 2008 · External reference
Phase I trial of docetaxel and thalidomide: a regimen based on metronomic therapeutic principles
10.1007/s10637-008-9137-0 · 2008 · External reference
Phase I trial of docetaxel given every 3weeks and daily lenalidomide in patients with advanced solid tumors
10.1007/s10637-008-9200-x · 2009 · External reference
A pharmacokinetic and safety study of intravenous arsenic trioxide in adult cancer patients with renal impairment
10.1007/s00280-009-1169-4 · 2010 · External reference
Dose-escalating and pharmacological study of oxaliplatin in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study
10.1200/jco.2003.11.015 · 2003 · External reference
Administration of oxaliplatin to patients with renal dysfunction: a preliminary report of the national cancer institute organ dysfunction working group
10.1016/s0093-7754(03)00401-9 · 2003 · External reference
Risks and benefits of phase 1 oncology trials, 1991 through 2002
10.1056/nejmsa042220 · 2005 · External reference
Amongst eligible patients, age and comorbidity do not predict for dose-limiting toxicity from phase I chemotherapy
10.1007/s00280-009-1084-8 · 2010 · External reference
